TELA Bio (TELA) Scheduled to Post Earnings on Thursday

TELA Bio (NASDAQ:TELA) is scheduled to be releasing its earnings data after the market closes on Thursday, November 7th. Analysts expect TELA Bio to post earnings of ($0.37) per share for the quarter. TELA Bio has set its FY 2024 guidance at EPS.Persons interested in registering for the company’s earnings conference call can do so using this link.

TELA Bio (NASDAQ:TELA) last posted its quarterly earnings data on Monday, August 12th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.45) by ($0.06). The company had revenue of $16.09 million for the quarter, compared to analysts’ expectations of $19.00 million. TELA Bio had a negative net margin of 65.04% and a negative return on equity of 252.57%. During the same quarter last year, the business posted ($0.46) EPS. On average, analysts expect TELA Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TELA Bio Trading Down 1.7 %

TELA Bio stock opened at $2.85 on Tuesday. The firm’s fifty day moving average price is $2.65 and its 200-day moving average price is $4.03. The company has a debt-to-equity ratio of 14.22, a quick ratio of 2.52 and a current ratio of 3.41. TELA Bio has a fifty-two week low of $2.30 and a fifty-two week high of $7.84.

Wall Street Analyst Weigh In

TELA has been the topic of a number of research reports. JMP Securities decreased their price objective on TELA Bio from $15.00 to $12.00 and set a “market outperform” rating on the stock in a report on Tuesday, August 13th. Lake Street Capital decreased their price target on shares of TELA Bio from $14.00 to $8.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Piper Sandler cut their price objective on shares of TELA Bio from $10.00 to $8.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. Finally, Canaccord Genuity Group reaffirmed a “buy” rating and set a $12.00 target price on shares of TELA Bio in a report on Friday, October 4th.

Insiders Place Their Bets

In related news, CTO Paul Talmo acquired 22,222 shares of the company’s stock in a transaction dated Thursday, October 24th. The stock was purchased at an average price of $2.25 per share, with a total value of $49,999.50. Following the completion of the purchase, the chief technology officer now owns 91,082 shares in the company, valued at $204,934.50. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other TELA Bio news, CEO Antony Koblish purchased 88,888 shares of TELA Bio stock in a transaction that occurred on Thursday, October 24th. The shares were bought at an average price of $2.25 per share, for a total transaction of $199,998.00. Following the acquisition, the chief executive officer now directly owns 458,897 shares in the company, valued at approximately $1,032,518.25. This trade represents a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CTO Paul Talmo purchased 22,222 shares of the stock in a transaction on Thursday, October 24th. The shares were acquired at an average cost of $2.25 per share, with a total value of $49,999.50. Following the transaction, the chief technology officer now directly owns 91,082 shares in the company, valued at $204,934.50. The trade was a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 182,220 shares of company stock valued at $409,995 in the last ninety days. Company insiders own 6.00% of the company’s stock.

About TELA Bio

TELA Bio, Inc, a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs.